Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 6
Submit an article Journal homepage
602
Views
16
CrossRef citations to date
0
Altmetric
Drug Evaluation

MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis

Mary Y Hu Gastroenterology Fellow Harvard Medical School, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Dana 501, Boston, MA 02215, USA
, MD &
Mark A Peppercorn Professor of Medicine Harvard Medical School, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Rabb 435, Boston, MA 02215, USA +1 617 667 8926; +1 617 667 1071; [email protected]
, MD
Pages 1049-1058 | Published online: 01 Apr 2008

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Daniel B Zandman & Mark A Peppercorn. (2009) Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine. Patient Preference and Adherence 3, pages 87-92.
Read now

Articles from other publishers (15)

Francesca Ferretti, Rosanna Cannatelli, Maria Camilla Monico, Giovanni Maconi & Sandro Ardizzone. (2022) An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. Journal of Clinical Medicine 11:9, pages 2302.
Crossref
Pedro M. Veloso, Raul Machado & Clarisse Nobre. (2021) Mesalazine and inflammatory bowel disease – From well-established therapies to progress beyond the state of the art. European Journal of Pharmaceutics and Biopharmaceutics 167, pages 89-103.
Crossref
Virginia Solitano, Ferdinando D’Amico, Gionata Fiorino, Kristine Paridaens, Laurent Peyrin-Biroulet & Silvio Danese. (2020) Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. Journal of Clinical Medicine 9:9, pages 2905.
Crossref
Stephanie A. Flowers, Shubha Bhat & James C. Lee. (2020) Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40:7, pages 704-712.
Crossref
Marie Wahlgren, Magdalena Axenstrand, Åsa Håkansson, Ali Marefati & Betty Lomstein Pedersen. (2019) In Vitro Methods to Study Colon Release: State of the Art and An Outlook on New Strategies for Better In-Vitro Biorelevant Release Media. Pharmaceutics 11:2, pages 95.
Crossref
Shuangxi Chen, Feng Guo, Tiantian Deng, Siqi Zhu, Wenyu Liu, Haijun Zhong, Hua Yu, Rong Luo & Zeyuan Deng. (2016) Eudragit S100-Coated Chitosan Nanoparticles Co-loading Tat for Enhanced Oral Colon Absorption of Insulin. AAPS PharmSciTech 18:4, pages 1277-1287.
Crossref
E. Merino Gallego, F. Gallardo Sánchez, A. Hernández Martínez, A. Pérez González, L. Miras Lucas, C. Heredia Carrasco & F.J. Gallego Rojo. (2017) Experiencia clínica en el tratamiento con mesalazina MMX en monoterapia en los pacientes con colitis ulcerosa. Enfermedad Inflamatoria Intestinal al Día 16:2, pages 45-50.
Crossref
Luca Palugan, Matteo Cerea, Lucia Zema, Andrea Gazzaniga & Alessandra Maroni. (2015) Coated pellets for oral colon delivery. Journal of Drug Delivery Science and Technology 25, pages 1-15.
Crossref
Tiago Sousa, Vipul Yadav, Vanessa Zann, Anders Borde, Bertil Abrahamsson & Abdul W. Basit. (2014) On the Colonic Bacterial Metabolism of Azo-Bonded Prodrugsof 5-Aminosalicylic Acid. Journal of Pharmaceutical Sciences 103:10, pages 3171-3175.
Crossref
Atsushi Sakuraba. 2014. Medical Therapy of Ulcerative Colitis. Medical Therapy of Ulcerative Colitis 55 68 .
Alessandra Maroni, Maria Dorly Del Curto, Lucia Zema, Anastasia Foppoli & Andrea Gazzaniga. (2013) Film coatings for oral colon delivery. International Journal of Pharmaceutics 457:2, pages 372-394.
Crossref
Wolfgang Kruis, Ludger Leifeld, Julia Morgenstern, Roland Pfützer, Birgitta Reimers & Sabine Ceplis-Kastner. (2013) The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: An observational study. Journal of Crohn's and Colitis 7:4, pages e125-e132.
Crossref
Ahmed Abd Elbary, Ahmed A. Aboelwafa & Ibrahim M. Al Sharabi. (2011) Once Daily, High-Dose Mesalazine Controlled-Release Tablet for Colonic Delivery: Optimization of Formulation Variables Using Box–Behnken Design. AAPS PharmSciTech 12:4, pages 1454-1464.
Crossref
Frank Hoentjen, Atsushi Sakuraba & Stephen Hanauer. (2011) Update on the Management of Ulcerative Colitis. Current Gastroenterology Reports 13:5, pages 475-485.
Crossref
Brendan J.R. Whittle & Csaba Varga. (2010) New light on the anti-colitic actions of therapeutic aminosalicylates: the role of heme oxygenase. Pharmacological Reports 62:3, pages 548-556.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.